E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Growth Disorders, Growth Retardation |
|
E.1.1.1 | Medical condition in easily understood language |
Growth failure seen in children |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To show an increase in annual growth rate 3 years after Visit 2. anual growth rate in standard deviation (SD) after 3 years will be compared to growth rate before the start of growth hormone (GH) treatment. |
|
E.2.2 | Secondary objectives of the trial |
To estimate the evolution of height under GH treatment after 1, 2 and 3 years
To estimate the growth rate 1 and 2 years after inclusion in the study
To confirm the good clinical and biological safety of GH treatment in such children
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. For GH treatment issue bone age should be less than (<) 13 years for a boy and < 11 years for a girl.2. Naïve child: with measured height should be < 2.5 SD for chronological age (CA).
Child currently treated by GH should have annual growth rate greater than equal to (>=) +1 SD and measured height <-2.5 SD for CA at the time GH was started.
3. Documented disease or pathological conditions known to be associated with growth
retardation and/or an adult height < -2 SD.
4. Children with the same pathological condition or disease.
5. Genotonorm treatment can be initiated by a physician according to the French SCP. that is to say a physician working in a hospital pediatric department or in a hospital endocrinology and metabolic disease department and, who is a pediatrician and/or a pediatric endocrinologist
6. The child benefits of the French social security cover.
|
|
E.4 | Principal exclusion criteria |
1. Idiopathic short stature.
2. Pathological condition or disease for which GH treatment is already approved in France.
3. Glucose intolerance on an oral glucose tolerance test dated less than 3 months or diabetes mellitus.
4. Syndrome known to be associated with an increased risk of cancer example. family history of adenomatous polyposis.
5. Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study.
6. Unable and/or unlikely to comprehend and/or follow GH treatment and/or the
protocol.
7. A previous history of intolerance or hypersensitivity to the study drug, or to drugs with similar chemical structures.
8. Subjects who are known or are suspected allergic to the preservative metacresol.
9. Pharmacological treatment with steroids for 1 year or more.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1) Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population
2) Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Per-Protocol (PP) Population
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1) Baseline, Month 36
2) Baseline, Month 36
|
|
E.5.2 | Secondary end point(s) |
1) Change From Baseline in Annual Growth Rate at Month 12, Month 24 and Month 36 in ITT Population
2) Change From Baseline in Annual Growth Rate at Month 12, Month 24, Month 36 in PP Population
3) Height
4) Change From Baseline in Height at Month 12, Month 24 and Month 36
5) Mean Height Standard Deviation Score (SDS) for Chronological Age (CA)
6) Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, Month 24 and Month 36
7) Mean Height Standard Deviation Score (SDS) for Bone Age (BA)
8) Change From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, Month 24 and Month 36
9) Baseline, Month 12, Month 24, Month 36
10) Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12 and Month 24 in ITT Population
11) Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12 and Month 24 in PP Population
12) Mean Growth Rate Standard Deviation Score (SDS) for Bone Age (BA)
13) Body Mass Index (BMI)
14) Change From Baseline in Body Mass Index (BMI) at Month 12, Month 24 and Month 36
15) Change From Baseline in Bone Age (BA) at Month 12, Month 24 and Month 36
16) Ratio of Bone Age (BA) to Chronological Age (CA) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline, Month 12, Month 24 and Month 36
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 19 |